Gilead Initiates FDA Priority Review for New HIV Treatment Combination

Gilead's Innovative HIV Treatment Combination

In an influential step towards enhancing HIV treatment options, Gilead Sciences has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for the innovative combination of Bictegravir (BIC) and Lenacapavir (LEN). This combination is intended for once-daily use in adult HIV patients who have achieved viral suppression. As the FDA has designated this application for priority review, the anticipated target date for completion is set for August 27, 2026, under the Prescription Drug User Fee Act (PDUFA).

The combination of Bictegravir and Lenacapavir presents a significant advancement in HIV treatment due to its robust resistance barrier and simplified daily dosing regimen. Bictegravir, an integrase strand transfer inhibitor (INSTI), offers a high barrier to resistance itself, while Lenacapavir stands out as the first-in-class capsid inhibitor. This unique pairing is expected to offer a viable treatment option for HIV patients, including those who may have complex treatment histories or who experience difficulties with multiple tablet regimens.

Gilead's Chief Medical Officer, Dr. Dietmar Berger, emphasized the potential impact of this single tablet regimen, stating, "The combination of Bictegravir and Lenacapavir could provide an important and effective treatment option for a diverse group of HIV-positive individuals, including older patients and those with comorbidities who seek to optimize their treatment regimens."

Clinical Data Supporting the NDA

The NDA submission is backed by promising clinical trial data from the Phase III ARTISTRY-1 and ARTISTRY-2 studies, which evaluated the transition from current regimens to BIC/LEN for patients who maintained viral suppression on complex multi-tablet regimens. Results indicated that the new regimen performed comparably to the control group regarding viral suppression at the 48-week mark, with an overall favorable safety profile. No significant or emerging safety concerns were reported during these trials.

Notably, the ARTISTRY-1 trial involved the oldest patient population ever registered in a Phase III HIV treatment study, underscoring the inclusive nature of the research. Data presented at CROI 2026 revealed that transitioning to BIC/LEN from complex regimens led to improvements in fasting lipid parameters and overall treatment satisfaction reported by patients. A key finding from ARTISTRY-2 indicated that the switch to BIC/LEN had no significant impact on weight, alleviating concerns regarding potential adverse effects.

Gilead's Ongoing Commitment to HIV Treatment

Jared Baeten, Gilead’s Senior Vice President of Clinical Development and Head of the HIV Division, stated, "As the needs of individuals living with HIV evolve, we are committed to developing innovative therapies that address their unique preferences. The potential approval of BIC/LEN will significantly contribute to meeting these evolving needs while reinforcing Gilead’s foundation of trusted, effective treatments in HIV care."

Currently, the BIC/LEN combination is still in the development phase, with no approvals existing globally. Its safety and efficacy remain unestablished pending further results.

Bictegravir is noted for its minimal use in conjunction with other HIV medications and is part of the first single-tablet regimen that requires no booster. Lenacapavir, meanwhile, is indicated for both treatment in adults with multi-drug resistant HIV and as a pre-exposure prophylaxis (PrEP) for those at risk of HIV infection, emphasizing its versatility and groundbreaking mechanism of action in inhibiting multiple stages of the HIV life cycle.

Future Outlook for HIV Treatment

Gilead Sciences has been a pioneer in HIV research for over 35 years, having developed foundational therapies that have turned HIV into a manageable chronic condition for millions of individuals globally. As part of its overarching mission, Gilead continues to invest in scientific innovation aimed at addressing the ever-changing needs of the HIV-positive population, striving towards an end to the HIV epidemic through partnerships and philanthropic efforts.

Through a planned investment of $32 billion by 2025, Gilead aims to enhance its operational foundation in the U.S. and continue to deliver significant advancements in the prevention and treatment of HIV, cancer, and inflammation.

As Gilead moves forward with the BIC/LEN regimen's review, both healthcare providers and patients look forward to the potential inclusion of this innovative therapy in the HIV treatment landscape, hoping for improved outcomes and a better quality of life for those affected by HIV.